The present invention relates, in general, to obesity, and, in particular,
to a method of treating obesity and minimizing metabolic risk factors
associated therewith using, for example, zonisamide or other weight-loss
promoting anticonvulsant either alone or in combination with bupropion or
other compound that enhances the activity of norepinephrine and/or
dopamine via uptake inhibition or other mechanism.